Thrombosis in end-stage renal disease

被引:127
作者
Casserly, LF [1 ]
Dember, LM [1 ]
机构
[1] Boston Univ, Sch Med, Dept Med, Renal Sect, Boston, MA 02118 USA
关键词
D O I
10.1046/j.1525-139X.2003.16048.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Although renal failure has classically been associated with a bleeding tendency, thrombotic events are common among patients with end-stage renal disease (ESRD). A variety of thrombosis-favoring hematologic alterations have been demonstrated in these patients. In addition, "nontraditional" risk factors for thrombosis, such as hyperhomocysteinemia, endothelial dysfunction, inflammation, and malnutrition, are present in a significant proportion of chronic dialysis patients. Hemodialysis (HD) vascular access thrombosis, ischemic heart disease, and renal allograft thrombosis are well-recognized complications in these patients. Deep venous thrombosis and pulmonary embolism are viewed as rare in chronic dialysis patients, but recent studies suggest that this perception should be reconsidered. Several ESRD treatment factors such as recombinant erythropoietin (EPO) administration, dialyzer bioincompatibilty, and calcineurin inhibitor administration may have prothrombotic effects. In this article we review the pathogenesis and clinical manifestations of thrombosis in ESRD and evaluate the evidence that chronic renal failure or its management predisposes to thrombotic events.
引用
收藏
页码:245 / 256
页数:12
相关论文
共 219 条
[1]   INDUCTION OF THROMBOSES WITHIN RENAL GRAFTS BY HIGH-DOSE PROPHYLACTIC OKT3 [J].
ABRAMOWICZ, D ;
PRADIER, O ;
MARCHANT, A ;
FLORQUIN, S ;
DEPAUW, L ;
VEREERSTRAETEN, P ;
KINNAERT, P ;
VANHERWEGHEM, JL ;
GOLDMAN, M .
LANCET, 1992, 339 (8796) :777-778
[2]   Erythropoietin for end-stage renal disease [J].
Adamson, JW ;
Eschbach, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :625-627
[3]   COMPLICATIONS AND LONG-TERM OUTCOME AFTER PERCUTANEOUS CORONARY ANGIOPLASTY IN CHRONIC-HEMODIALYSIS PATIENTS [J].
AHMED, WH ;
SHUBROOKS, SJ ;
GIBSON, CM ;
BAIM, DS ;
BITTL, JA .
AMERICAN HEART JOURNAL, 1994, 128 (02) :252-255
[4]   EFFECT OF HEMODIALYSIS ON PROTEIN-C LEVELS [J].
ALEGRE, A ;
VICENTE, V ;
GONZALEZ, R ;
ALBERCA, I .
NEPHRON, 1987, 46 (04) :386-387
[5]  
ALLEN RDM, 1987, SURG GYNECOL OBSTET, V164, P137
[6]   LOW-DOSE DANAZOL IS EFFECTIVE IN MANAGEMENT OF ERYTHROPOIETIN INDUCED THROMBOSIS [J].
ALMOMEN, AK ;
HURAIB, SO ;
GADER, AMA ;
SULAIMANI, F .
THROMBOSIS RESEARCH, 1991, 64 (05) :527-532
[7]   Impaired endothelium-dependent vasodilatation in renal failure in humans [J].
Annuk, M ;
Lind, L ;
Linde, T ;
Fellström, B .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (02) :302-306
[8]  
Bakir N, 1996, NEPHROL DIAL TRANSPL, V11, P140
[9]   Hypercoagulopathy in a hemodialysis patient:: Are elevations in factors VII and VIII effective? [J].
Baskin, E ;
Duman, Ö ;
Besbas, N ;
Ozen, S .
NEPHRON, 1999, 83 (02) :180-180
[10]  
Beathard GA, 1995, J AM SOC NEPHROL, V6, P1619